BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34422248)

  • 1. Basic Pan-Cancer Analysis of the Carcinogenic Effects of Cyclin-Dependent Kinase 4 (CDK4) in Human Surface Tumors.
    Wu J; Deng T; Huang Y; Cheng H
    J Healthc Eng; 2021; 2021():8493572. PubMed ID: 34422248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
    Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
    J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis.
    Jirawatnotai S; Sharma S; Michowski W; Suktitipat B; Geng Y; Quackenbush J; Elias JE; Gygi SP; Wang YE; Sicinski P
    Cell Cycle; 2014; 13(18):2889-900. PubMed ID: 25486477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coordinated expression of cyclin-dependent kinase-4 and its regulators in human oral tumors.
    Poi MJ; Knobloch TJ; Sears MT; Uhrig LK; Warner BM; Weghorst CM; Li J
    Anticancer Res; 2014 Jul; 34(7):3285-92. PubMed ID: 24982332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
    Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
    J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.
    Shi CJ; Xu SM; Han Y; Zhou R; Zhang ZY
    Melanoma Res; 2021 Dec; 31(6):495-503. PubMed ID: 34483306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
    Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
    J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
    Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
    J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.
    Sotillo R; Dubus P; Martín J; de la Cueva E; Ortega S; Malumbres M; Barbacid M
    EMBO J; 2001 Dec; 20(23):6637-47. PubMed ID: 11726500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous melanoma arising in agminated melanocytic nevi: CDKN2A and CDK4 mutation screening.
    Rezze GG; Leon A; Silva DC; Neves RI; Molina GC; Carraro DM; Landman G; Duprat JP
    Acta Derm Venereol; 2012 Jan; 92(1):98-9. PubMed ID: 21710107
    [No Abstract]   [Full Text] [Related]  

  • 15. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
    Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
    Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
    Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
    In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors.
    Cui X; Zhang X; Liu M; Zhao C; Zhang N; Ren Y; Su C; Zhang W; Sun X; He J; Gao X; Yang J
    Genomics; 2020 Nov; 112(6):3958-3967. PubMed ID: 32645525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence.
    Rane SG; Cosenza SC; Mettus RV; Reddy EP
    Mol Cell Biol; 2002 Jan; 22(2):644-56. PubMed ID: 11756559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.
    Perez M; Muñoz-Galván S; Jiménez-García MP; Marín JJ; Carnero A
    Oncotarget; 2015 Dec; 6(38):40557-74. PubMed ID: 26528855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
    Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
    Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.